Neuroleptic-induced catalepsy as a model of Parkinson's disease. I. Effect of dopaminergic agents.
Catalepsy was observed in the rat following intrastriatal injections of the dopamine antagonists sulpiride or fluphenazine and after subcutaneous administration of fluphenazine. The neuroleptic-induced catalepsy was reversed by the classical anti-parkinsonian agent L-DOPA and by agents that function through dopamine systems such as d- and methamphetamine and the direct D2 receptor agonist quinpirole. The D1 agonist SKF 38393, and the D1/D2 agonist apomorphine, were ineffective in this model. These results support limited use of the rat catalepsy model for the screening of potential anti-parkinsonian compounds and indicate that this procedure can provide valuable information concerning striatal dopamine function.
Elliott
P J
PJ
Glaxo Group Research Ltd., Neuropharmacology Department, Ware, Hertfordshire, United Kingdom.
Close
S P
SP
Walsh
D M
DM
Hayes
A G
AG
Marriott
A S
AS
D000818:Animals; D014150:Antipsychotic Agents / Q000494:pharmacology*; D002375:Catalepsy / Q000139:chemically induced* / Q000503:physiopathology; D004195:Disease Models, Animal; D004298:Dopamine / Q000502:physiology*; D004305:Dose-Response Relationship, Drug; D005476:Fluphenazine / Q000494:pharmacology*; D007980:Levodopa / Q000627:therapeutic use; D008297:Male; D008694:Methamphetamine / Q000627:therapeutic use; D008845:Microinjections; D010300:Parkinson Disease / Q000188:drug therapy / Q000378:metabolism / Q000503:physiopathology*; D051381:Rats; D013469:Sulpiride / Q000494:pharmacology*
D014150:Antipsychotic Agents; D008694:Methamphetamine; D007980:Levodopa; D013469:Sulpiride; D005476:Fluphenazine; D004298:Dopamine